Willibald Hochholzer

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Novel biomarkers in cardiovascular disease: update 2010
    Willibald Hochholzer
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am Heart J 160:583-94. 2010
  2. ncbi Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy
    Willibald Hochholzer
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 162:518-26.e5. 2011
  3. ncbi Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement
    Willibald Hochholzer
    Herz Zentrum Bad Krozingen, Bad Krozingen, Germany
    J Am Coll Cardiol 55:2427-34. 2010
  4. ncbi Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement
    Dietmar Trenk
    Herz Zentrum Bad Krozingen, Suedring 15, 79189 Bad Krozingen, Germany
    Thromb Haemost 99:174-81. 2008
  5. ncbi Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
    Dietmar Trenk
    Herz Zentrum Bad Krozingen, Bad Krozingen, Germany
    J Am Coll Cardiol 51:1925-34. 2008
  6. ncbi Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement
    Willibald Hochholzer
    Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
    J Am Coll Cardiol 48:1742-50. 2006
  7. ncbi Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement
    Dietmar Trenk
    Herz Zentrum Bad Krozingen, Germany
    Circ Cardiovasc Genet 4:429-36. 2011
  8. ncbi Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-
    Willibald Hochholzer
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Circulation 123:2681-9. 2011
  9. ncbi Antiplatelet response to the 150-mg maintenance dose of clopidogrel in patients with insufficient platelet inhibition after clopidogrel loading for elective coronary stent placement
    Dietmar Trenk
    Herz Zentrum Bad Krozingen, Bad Krozingen, Germany
    EuroIntervention 4:214-21. 2008
  10. ncbi Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 306:2221-8. 2011

Detail Information

Publications19

  1. ncbi Novel biomarkers in cardiovascular disease: update 2010
    Willibald Hochholzer
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am Heart J 160:583-94. 2010
    ..Further evaluation is needed before these markers can be adopted routinely in clinical practice...
  2. ncbi Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy
    Willibald Hochholzer
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 162:518-26.e5. 2011
    ..The aims of this analysis were to evaluate the impact of smoking on the antiplatelet effect of clopidogrel and prasugrel and to test the potential interaction of smoking with the treatment effect of these drugs...
  3. ncbi Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement
    Willibald Hochholzer
    Herz Zentrum Bad Krozingen, Bad Krozingen, Germany
    J Am Coll Cardiol 55:2427-34. 2010
    ..The aim of this study was to evaluate the relative impact of demographic and clinical variables versus the cytochrome P450 2C19 (CYP2C19) polymorphism on antiplatelet effects of clopidogrel...
  4. ncbi Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement
    Dietmar Trenk
    Herz Zentrum Bad Krozingen, Suedring 15, 79189 Bad Krozingen, Germany
    Thromb Haemost 99:174-81. 2008
    ..645). Thus, peri-interventional atorvastatin and simvastatin had no effect on the antiplatelet activity of a loading dose of clopidogrel 600 mg and did not affect clinical outcome after PCI...
  5. ncbi Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
    Dietmar Trenk
    Herz Zentrum Bad Krozingen, Bad Krozingen, Germany
    J Am Coll Cardiol 51:1925-34. 2008
    ....
  6. ncbi Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement
    Willibald Hochholzer
    Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
    J Am Coll Cardiol 48:1742-50. 2006
    ..04 to 1.61; p = 0.026). CONCLUSIONS: The level of platelet aggregation immediately before elective coronary stenting in patients pre-treated with a high loading dose of clopidogrel is correlated with early outcome after the procedure...
  7. ncbi Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement
    Dietmar Trenk
    Herz Zentrum Bad Krozingen, Germany
    Circ Cardiovasc Genet 4:429-36. 2011
    ..We sought to investigate whether the PON1 Q192R gene polymorphism affects platelet reactivity in patients undergoing elective coronary stent placement...
  8. ncbi Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-
    Willibald Hochholzer
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Circulation 123:2681-9. 2011
    ....
  9. ncbi Antiplatelet response to the 150-mg maintenance dose of clopidogrel in patients with insufficient platelet inhibition after clopidogrel loading for elective coronary stent placement
    Dietmar Trenk
    Herz Zentrum Bad Krozingen, Bad Krozingen, Germany
    EuroIntervention 4:214-21. 2008
    ..Our prospective study sought to investigate whether inadequate platelet responses to clopidogrel can be corrected by increasing the daily maintenance dose from 75 mg to 150 mg...
  10. ncbi Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 306:2221-8. 2011
    ..Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel...
  11. ncbi New definition of myocardial infarction: impact on long-term mortality
    Willibald Hochholzer
    Herz Zentrum, Bad Krozingen, Germany
    Am J Med 121:399-405. 2008
    ....
  12. ncbi Whole blood aggregometry for evaluation of the antiplatelet effects of clopidogrel
    Willibald Hochholzer
    Herz Zentrum Bad Krozingen, D 79189 Bad Krozingen, Germany
    Thromb Res 119:285-91. 2007
    ..Established methods for monitoring antiplatelet drug activity such as optical aggregometry and determination of surface protein expression are not suitable for routine bedside testing...
  13. ncbi Novel biomarkers in cardiovascular disease: research tools or ready for personalized medicine?
    Christian Stratz
    Herz Zentrum Bad Krozingen, Südring 15, Bad Krozingen, Germany
    Cardiol Rev 20:111-7. 2012
    ..Although many biomarkers may be useful for prognostication, very few have been shown to improve the treatment of patients with cardiovascular disease when implemented in a clinical setting...
  14. ncbi The facts behind niacin
    Willibald Hochholzer
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Ther Adv Cardiovasc Dis 5:227-40. 2011
    ..However, the clinical significance of these surrogate markers has been questioned. Two large randomized trials will address whether niacin-statin combination therapy is an appropriate therapeutic alternative to statin monotherapy...
  15. ncbi Platelet activation and myocardial necrosis in patients undergoing radiofrequency and cryoablation of isthmus-dependent atrial flutter
    Willibald Hochholzer
    Herz Zentrum Bad Krozingen, Suedring 15, 79189, Bad Krozingen, Germany
    Europace 9:490-5. 2007
    ..Due to the delayed occurrence of cryolesions it is currently unknown, if cryoenergy and RF energy are associated with similar platelet activation and myocardial necrosis in the days after the procedure...
  16. ncbi The impact of platelet count on mortality in unstable angina/non-ST-segment elevation myocardial infarction
    Christian Mueller
    Herz Zentrum, Bad Krozingen, Germany
    Am Heart J 151:1214.e1-7. 2006
    ..Therefore, we sought to determine the impact of platelet count on long-term outcome in unstable angina/non-ST-segment elevation myocardial infarction (UA/NSTEMI) receiving contemporary treatment...
  17. ncbi Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention
    Willibald Hochholzer
    Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
    Circulation 111:2560-4. 2005
    ..CONCLUSIONS: After loading with 600 mg of clopidogrel, the full antiplatelet effect of the drug is achieved after 2 hours. Statins do not interfere with the level of platelet inhibition after this dose...
  18. ncbi Does it make sense to combine statins with other lipid-altering agents following AIM-HIGH, SHARP and ACCORD?
    Willibald Hochholzer
    Universitaets Herzzentrum Freiburg Bad Krozingen, Suedring 15, 79189, Bad Krozingen, Germany
    Curr Atheroscler Rep 15:290. 2013
    ..Although there is currently no evidence that any of the potential therapy combinations can improve clinical outcome compared to statin monotherapy alone, results of several large ongoing trials will help to clarify this important field...
  19. ncbi Lipid lowering goals: back to nature?
    Willibald Hochholzer
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Ther Adv Cardiovasc Dis 4:185-91. 2010
    ..To date, achieving such low lipid levels appears safe, but the generalizability of these findings to broader populations and the clinical benefit on the reduction of cardiovascular complications remains to be proven...